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A B S T R A C T
Purpose
Racial variation in the financial impact of cancer may contribute to observed differences in the use of 
guideline-recommended treatments. We describe racial differences with regard to the financial 
impact of breast cancer in a large population-based prospective cohort study.
Methods
The Carolina Breast Cancer Study oversampled black women and women younger than age 50 
years with incident breast cancer in North Carolina from 2008 to 2013. Participants provided medical 
records and data regarding demographics, socioeconomic status, and financial impact of cancer at 5 
and 25 months postdiagnosis. We report unadjusted and adjusted financial impact at 25 months 
postdiagnosis by race.
Results
The sample included 2,494 women who completed follow-up surveys (49% black, 51% white). 
Since diagnosis, 58% of black women reported any adverse financial impact of cancer (v 39% of 
white women; P , .001). In models adjusted for age, stage at diagnosis, and treatment received, 
black women were more likely to report adverse financial impact attributable to cancer (adjusted risk 
difference [aRD], +14 percentage points; P , .001), including income loss (aRD, +10 percentage 
points; P , .001), health care–related financial barriers (aRD, +10 percentage points; P , .001), 
health care–related transportation barriers (aRD, +10 percentage points; P , .001), job loss (aRD, 
6 percentage points; P , .001), and loss of health insurance (aRD, +3 percentage points; P , .001). 
The effect of race was attenuated when socioeconomic factors were included but remained sig-
nificant for job loss, transportation barriers, income loss, and overall financial impact.
Conclusion
Compared with white women, black women with breast cancer experience a significantly worse 
financial impact. Disproportionate financial strain may contribute to higher stress, lower treatment 
compliance, and worse outcomes by race. Policies that help to limit the effect of cancer-related 
financial strain are needed.
J Clin Oncol 36:1695-1701. 
INTRODUCTION
With cancer care costs rising rapidly,1 patients
often are burdened by the cost of their treatment,
yet financial toxicity is rarely discussed in the
clinic, and many patients and providers have little
guidance about where to turn for assistance with
financial burden.2 The rising cost of cancer care
not only is an increasingly recognized problem on
a societal level but also is a potentially devastating
facet of the cancer experience for patients.3
Studies have suggested that patients with cancer
carry a high burden of financial distress and are
more likely to experience financial crises, such as
bankruptcy.4 Financial toxicity has been shown to
affect both survival and overall quality of life
adversely.5,6
Having health insurance does not necessarily
protect against the financial distress associated
with cancer. One study found that 42% of insured
patients with cancer report significant or cata-
strophic financial burden,7 and a large majority
applied for copayment assistance for medications.
Many patients have reported wanting to discuss
the costs of cancer treatments with their physi-
cians but not having such conversations,8,9 which
may be due to cost-benefit information often
being opaque to providers as well as to patients
and providers not knowing where to direct
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patients for financial assistance. As a result, many patients with
cancer and their families face difficult decisions on their own and
forego, delay, or discontinue treatment in light of competing
demands.
An understanding of the effects of financial burden among
racial minorities, who shoulder a greater burden of poor cancer
outcomes, is important.10 Black patients with breast cancer, in
particular, have higher mortality and lower initiation of and ad-
herence to guideline-recommended treatments,11-13 which may be
closely related to their inability to pay for care. We leveraged
a unique prospective cohort enriched for young and working-age




Women were recruited in 2008 to 2013 across 44 counties at the time
of diagnosis by rapid case ascertainment through the North Carolina state
cancer registry. The Carolina Breast Cancer Study is purposefully enriched
such that one half of all participants are black and one half are younger
than age 50 years.14 Participants provided consent for access to medical
records and self-reported survey data on demographics, socioeconomic
status, health-related quality of life, access to care, treatment experiences,
and financial impact of cancer at approximately 5 months (baseline) and
25 months (follow-up) postdiagnosis. Study retention was high, with
89.6% of eligible women completing the follow-up survey. Ongoing data
collection within this prospective cohort study continues, with final follow-
up data expected approximately 10 years postdiagnosis for all participants.
This study was approved by the University of North Carolina at Chapel Hill
institutional review board.
Financial Impact Measures
We conceptualized financial impact using a modified model from
the National Cancer Institute that describes the direct and indirect
contributors to adverse financial impact.15 We modified this model to
describe how race is related to multiple factors that directly influence
adverse financial impact (Fig 1). Several questions related to financial
impact of cancer diagnosis were self-reported by women at 25 months
postdiagnosis.
Women reported having lost a job and/or income as a result of breast
cancer. Those who reported never having worked (n = 15) and who
declined to respond about their employment (n = 38) were excluded from
the analysis for both of these employment-related outcomes. In addition,
women reported whether they had been unable to access any medical care
as a result of financial and/or transportation barriers since the time of
diagnosis. In a separate question, they were asked whether they refused or
delayed any recommended cancer treatment because of cost and/or
transportation. These health care access and treatment refusal/delay
questions were combined into one indicator each for financial and
transportation barriers to care after diagnosis.
We also assessed loss of private insurance during the study period to
estimate cancer-attributable financial burden. We focused on insurance
changes that were likely to result from cancer treatment that rendered
women unable to work or to afford private insurance premiums (as
opposed to changes in public insurance primarily driven by entitlement
programs on the basis of eligibility). Women’s insurance status and type of
insurance were assessed at both time points. Those who self-identified as
having private insurance during the 5-month survey but who were un-
insured at the 25-month survey were coded as having lost private in-
surance. Analyses for this variable, therefore, restricted the sample to
only women who had private insurance at the time of the first survey
(n = 1,834). Finally, we assessed a measure of any adverse financial outcome
as a summary indicator that reflected whether an individual reported one
or more of the five outcomes studied.
Control Variables
The primary analyses control for clinical differences (eg, tumor stage)
that may vary by race and lead to differences in clinical decision making
and treatment-related costs. Medical record abstraction was used to de-
termine tumor stage and treatment history and measured using binary
indicators for receipt of mastectomy, chemotherapy, radiation therapy,
trastuzumab, and adjuvant endocrine therapy. Comorbidity burden also
may vary by race and influence the extent of financial burden and was
measured from medical records at the time of diagnosis, including obesity,
diabetes, chronic obstructive pulmonary disease, hypertension, and heart
disease. Age was self-reported at the baseline survey.
In secondary analyses, we added to the models socioeconomic
variables that may vary by race and influence one’s ability to cope
financially with high medical and nonmedical expenses. Educational
attainment, annual household income, and insurance status were self-
reported at baseline. Women could report more than one source of in-
surance, and these were organized into mutually exclusive categories such




















Fig 1. Conceptual framework. Concep-
tual model of racial differences in financial
impact. Modified from the National Cancer
Institute framework on health and financial
outcomes.15
Medicaid, and Medicare beneficiaries who also reported supplemental
private insurance were classified as having any private coverage. We also
included self-reported marital status as one measure of social support
because this has been associated with financial vulnerability and cancer
outcomes.16,17
Analysis
From 2,998 study participants, we excluded women who reported
a race other than black or white (n = 82) because it would be inappropriate
to analyze these individuals as one group, yet small sample sizes within
each category precluded analysis (Appendix Fig A1, online only). We also
excluded women who did not complete the follow-up survey (n = 422)
because of death (n = 120) or nonresponse (n = 302). Although small in
number, we found that those excluded because of death or nonresponse
often were, on average, black and younger, had a higher stage at diagnosis,
and were of lower socioeconomic status than those who completed the
follow-up (Appendix Table A1, online only). Any bias that resulted from
exclusion of these more vulnerable groups would likely be small but, if
anything, would have shifted the reported findings toward more con-
servative estimates of financial burden.
We first examined unadjusted racial differences in prevalence of
adverse financial impact. To account for a small number of women with
missing values for income (5%), tumor stage (2%), or baseline insurance
status (, 1%), we performed multiple imputation to estimate values for
missing variables. Fifty imputed data sets were created, with results
combined as described by Rubin.18 Sensitivity analysis using only complete
cases yielded similar findings for all outcomes.
By following recommendations by the Institute of Medicine,19 we
first specified multivariable logistic regressions for each of the six di-
chotomous outcomes of interest and adjusted for race and clinical dif-
ferences only. To determine the extent to which racial differences in adverse
financial impact were explained by differences in underlying socioeco-
nomic status, in secondary analyses, we added to these regressions so-
cioeconomic variables, including self-reported education, income, marital
status, and insurance status. We examinedmodel fit because these variables
were added sequentially. Among clinical variables, age was associated with
the largest improvement in model fit, and among socioeconomic variables,
income was associated with the largest increase in model fit, with insurance
also explaining a large portion of the variation. Results from the primary,
partially adjusted models can be interpreted as the total or joint effect of
race,20 whereas results from the secondary, fully adjusted models can be
interpreted as the direct residual effect of race.21
We also examined potential interactions between race and treatment
indicators for radiation therapy and endocrine therapy to explore whether
racial differences in financial burden exist within various treatment
subgroups. Because these findings were inconsistent in magnitude, di-
rection, and statistical significance and did not meaningfully improve
model fit, we reverted to and present our final models without interactions.
Regression results are presented as adjusted risk differences (aRDs),
which describe the absolute difference in the likelihood of each outcome
for black (relative to white) women, after controlling for other charac-
teristics.22 We also present adjusted risk ratios in Appendix Table A2
(online only).
Stata 13 software (StataCorp, College Station, TX) was used for the
statistical analysis. A significance level of .05 was used for all analyses.
RESULTS
The final sample included 1,265 white women and 1,229 black
women (Table 1). On average, women were 52 years of age at the
time of diagnosis, and black women were slightly but significantly
younger than white women (P = .01). Black women more often
presented with higher-stage disease at the time of diagnosis (P, .001)
and more often received chemotherapy (69% v 58%; P, .001) and
radiation therapy (75% v 70%; P = .003). Black women more often
thanwhite women presented with comorbid conditions at diagnosis,
including obesity (19% v 10%; P, .001), hypertension (58% v 31%;
P , .001), and diabetes (22% v 8%; P , .001). Black women also
weremore socioeconomically disadvantaged relative towhite women,
including having lower average household incomes, lower educa-
tion, and higher rates of both Medicaid and no insurance. Black
womenwere significantly less likely to bemarried thanwhite women
(43% v 72%; P , .001).
Negative financial impact was common among all breast
cancer survivors (48%), but prevalence was strikingly higher
among black versus white women (58% v 39%; P , .001). Since
diagnosis, black women more often lost private insurance (5% v
1%; P , .001), lost a job (14% v 6%; P , .001), or experienced
a financial barrier to health care (24% v 11%; P , .001). Black
women also were four times more likely to experience a trans-
portation barrier (14% v 3%; P, .001) than white women (Fig 2).
Adjustment for clinical differences explained some of the
variation in financial impact, but racial differences remained large
and statistically significant (Table 2; Appendix Table A1). Com-
pared with white women, black women were 14.1 percentage
points more likely to experience a financial impact (P, .001) and
after controlling for clinical differences, were significantly more
likely to experience each individual measure of financial impact,
including a financial barrier (aRD, +10.1 percentage points; P ,
.001), loss of income (aRD, +9.7 percentage points; P , .001),
transportation barrier (aRD, +9.6 percentage points; P , .001),
loss of a job (aRD, +6.4 percentage points; P , .001), and loss of
insurance (aRD, +2.8 percentage points; P , .001; Table 2).
Additional adjustment for socioeconomic characteristics
explained much of the racial differences for both income loss and
financial barriers to care. However, risk differences in other fi-
nancial outcomes, although attenuated, remained statistically
significant (Table 2). After controlling for income, insurance sta-
tus, marital status, and education, black women remained 5.4
percentage points more likely to experience any financial impact
(P = .01), 5.0 percentage points more likely to lose income (P = .02),
3.6 percentage points more likely to experience transportation
barriers (P = .002), and 4.0 percentage points more likely to lose
a job (P = .003) than white women.
In fully adjusted models, each additional year of age reduced
the risk of experiencing any financial impact by 0.7 percentage
points (P , .001; Table 3). Women with stage IV breast cancer at
diagnosis were more likely than those with stage I disease at di-
agnosis to experience any adverse financial impact (aRD, +14.1
percentage points; P = .02). Women who received chemotherapy
versus those who did not were 9.6 percentage points more likely to
experience an adverse financial impact (P, .001). Of note, receipt
of trastuzumab was negatively associated with experiencing a fi-
nancial barrier to care (aRD,25.2 percentage points; P = .003) but
not with other outcomes.
Compared with women with an annual income . $50,000,
those with an annual income of $15,000 to $29,999 more often
reported any adverse financial impact (aRD, +13.9 percentage
points; P , .001) and having experienced a reduction in income
(aRD, +8.8 percentage points; P = .02), a financial barrier to care
(aRD, +14.0 percentage points; P , .001), and a loss of insurance
(aRD, +2.7 percentage points; P = .002; Table 3). Women who
earned , $15,000 per year were most likely to report a trans-
portation barrier to care (aRD, +12.6 percentage points; P, .001)
compared with those who earned . $50,000 per year.
Insurance also was a strong predictive factor, with uninsured
women 28.4 percentage points more likely (P , .001) and
Medicaid-insured women 21.1 percentage points more likely (P,
.001) than the privately insured to experience any adverse financial
impact (Table 3). Medicaid enrollees were more likely than any
other group to experience transportation barriers (aRD, +10.3
percentage points; P , .001). Relative to being single, being
separated or divorced was associated with an increase of 4.5
percentage points in the probability of losing a job as a result of
cancer (P = .007) and a increase of 6.4 percentage points in the
probability of any adverse financial impact (P = .02; Table 3).
DISCUSSION
adverse financial impact is reported by more than one half of black
women and more than one third of white women, a large pro-
portion of which is attributable to lost income postdiagnosis. By
controlling for only clinical differences,20 we found that black
women were at greater risk than white women for all measured
adverse financial impacts. The effect of black race was somewhat
attenuated when baseline education, income, occupation, and
health insurance were also included in models but remained
significantly associated with the majority of adverse outcomes. The
remaining racial differences in adverse financial impact, once both
clinical and socioeconomic variables have been controlled for (the
direct residual effect), may reflect unmeasured differences in social
capital, household economic dynamics (eg, caregiving burden,
single-income households), or asset reserves that vary by race and
contribute to greater cancer-related financial strain among black
women.
High cancer-related financial burden has been shown to affect
treatment choice, treatment compliance, and cancer outcomes.6,23
Although prior studies have drawn attention to the increasing
burden of cancer-related financial toxicity,5,24,25 we are aware of no
study that has directly measured and reported on the extent of
racial and age-related differences in the financial burden of cancer
Table 1. Participant Characteristics by Race
Characteristic White, No. (%) Black, No. (%) P
Participants 1,265 (51.0) 1,229 (49.0)
Mean age at diagnosis, years (SD) 52.96 (11.2) 51.89 (10.9) .010
AJCC stage
1 630 (50.4) 458 (37.8) < .001
2 461 (36.9) 531 (43.8)
3 139 (11.1) 178 (14.7)
4 21 (1.7) 45 (3.7)
Treatment received
Mastectomy 657 (51.9) 585 (47.6) .030
Chemotherapy 731 (57.8) 845 (68.8) < .001
Radiation 889 (70.3) 921 (74.9) .009
Endocrine therapy 970 (76.7) 770 (62.7) < .001
Trastuzumab 167 (13.2) 198 (16.1) .040
Comorbidity
Obesity 126 (10.0) 239 (19.4) < .001
Hypertension 389 (30.8) 716 (58.3) < .001
Diabetes 100 (7.9) 267 (21.7) < .001
Annual household income, $
, 15,000 79 (6.6) 289 (24.8) < .001
15,000-29,999 155 (12.9) 300 (25.7)
30,000-49,999 208 (17.3) 239 (20.5)
50,000 761 (63.3) 338 (29.0)
Insurance status
Private 1,105 (87.4) 748 (60.9) < .001
Medicare 53 (4.2) 92 (7.5)
Medicaid 70 (5.5) 291 (23.7)
Uninsured 37 (2.9) 97 (7.9)
Educational attainment
Did not complete high school 54 (4.3) 142 (11.6) < .001
High school graduate 591 (46.7) 711 (57.9)
Some college/college graduate 620 (49.0) 376 (30.6)
Marital status
Single 58 (4.6) 230 (18.7) < .001
Married/living with partner 914 (72.3) 525 (42.7)
Widowed 83 (6.6) 121 (9.8)
Separated/divorced 210 (16.6) 353 (28.7)
NOTE. Analyses were t test for continuous variables or x2 test for categorical variables of black v white women. Bold indicates statistically significant (P , .05).
Abbreviations: AJCC, American Joint Committee on Cancer; SD, standard deviation.
Prevalence of adverse financial impact of cancer is high among 
all breast cancer survivors, and black women experience a dis-
proportionate share of this burden. Overall, the study found that
because of insufficient samples of black and young women. Be-
cause we oversampled both black and young women in equal
proportions, we can report on the experiences of these important
subpopulations who shoulder a greater burden of poor cancer
outcomes. Of note, racial and age-related disparities in breast
cancer outcomes13,26 may be related, at least in part, to cost-related
undertreatment.27,28 Prior studies of commercially insured pop-
ulations have shown that high out-of-pocket costs and younger age
are related to nonadherence to aromatase inhibitors but lack detail
on racial identification.28 An increased focus on financial strain as
a potential driver of outcome disparities may help to reduce
differences in recurrence and survival.29
Several limitations should be considered. First, this study
reflects racial differences within a single region that may not be
representative of experiences elsewhere, particularly in states where
additional policy differences, such as Medicaid expansion or out-
of-pocket restrictions on oral chemotherapy drug pricing, may
reduce overall cost burden for patients with cancer. Nevertheless,
North Carolina is an ideal state in which to examine these issues
because of its large size and socioeconomic diversity. Of North
Carolina’s 9.9 million residents, approximately 30% are minorities,
and 22% are African American compared with the national average
of 13%.30 Economic conditions are in line with national averages,
with slightly more than a quarter being college educated and 18%
living below the poverty line. Therefore, we believe that the
findings are largely generalizable, particularly for states with few
policies to address financial burden. In addition, we do not have
information that reflects actual out-of-pocket health care spending
for study participants, only a perceived burden as a result of cancer
care costs. However, our goal was to measure the differences in
patient-perceived rather than objective hardship as a result of high
cancer costs; therefore, we believe that our measure is an accurate
reflection of the effect of cancer costs on patients. Although we
recognize the vital importance of the Affordable Care Act–related
health insurance expansions that occurred during the study period,
which likely affected financial vulnerability, the study did not capture
longitudinal changes in health insurance enrollment with any
granularity. Future studies should examine in more detail the role of
insurance changes in cancer-related financial vulnerability over time
to ensure sufficient samples of public and private insurance plan
enrollees. Finally, we were limited to only 2 years of follow-up data,
but because Carolina Breast Cancer Study data capture is ongoing,
Table 2. Unadjusted and Adjusted Risk Differences of Race: Adverse Financial Impact of Breast Cancer
Model









1. Unadjusted effect of black race only (ref. white) +18.81§ (1.97) +13.25§ (1.98) +13.09§ (1.50) +11.39§ (1.12) +7.63§ (1.20) +3.37§ (0.83)
2. Partially adjusted, including clinical factors only +14.09§ (2.11) +9.69§ (2.12) +10.12§ (1.59) +9.59§ (1.14) +6.41§ (1.27) +2.82§ (0.84)
3. Fully adjusted, including clinical factors and
socioeconomic status
+5.42k (2.16) +5.03¶ (2.24) +2.71 (1.61) +3.63¶ (1.16) +4.03 (1.34) +1.32 (0.78)
NOTE. Results are interpreted as average change in predicted risk of outcome for black relative towhite. Adjusted results are from logistic regressions that controlled for
additional characteristics. Model 2 adjusts for stage, receipt of mastectomy, chemotherapy, radiation therapy, hormone therapy, trastuzumab, and comorbidity. Model 3
adjusts for all clinical characteristics plus insurance, household income, education, and marital status. Bold indicates statistically significant (P , .05).
Abbreviation: ref., referent.
*Analysis excludes women who had never worked before diagnosis or declined to respond (n = 2,440).
†Analysis excludes women who had never worked before diagnosis (n =2,480).



















































Fig 2. Unadjusted probability of adverse
financial impact by race. Bars represent SEs.
(*)P , .001, black versus white.
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Table 3. Fully Adjusted Risk Differences of Race and All Control Variables: Adverse Financial Impact of Breast Cancer
Variable
Adjusted Risk Difference (SE)
Any Financial Impact Income* Loss Financial Barrier Transport Barrier Job† Loss Insurance‡ Loss
Black race (ref. white) +5.42§ (2.16) +5.03§ (2.24) +2.71 (1.61) +3.63k (1.16) +4.03k (1.34) +1.32 (0.78)
Age 20.70¶ (0.10) 20.47¶ (0.11) 20.56¶ (0.08) 20.15§ (0.06) 20.18k (0.07) 20.12k (0.05)
Stage (ref. stage 1)
2 +2.14 (2.32) +3.12 (2.42) 22.88 (1.77) +1.25 (1.29) +0.90 (1.49) +0.18 (.87)
3 +5.46 (3.61) +3.75 (3.68) 21.93 (2.54) +0.55 (1.75) +0.41 (2.07) +0.20 (1.38)
4 +14.09§ (6.22) +14.70k (6.40) +2.04 (4.33) +4.33 (3.07) +10.00§ (4.48) 21.08 (1.55)
Treatment received
Mastectomy 21.36 (2.40) 22.03 (2.46) 20.04 (1.72) 20.02 (1.22) 22.98§ (1.42) +1.01 (0.97)
Chemotherapy +9.59¶ (2.53) +9.66¶ (2.61) +5.66¶ (1.79) +3.34k (1.29) +2.95 (1.54) +1.20 (0.85)
Radiation 20.06 (2.62) +0.83 (2.69) 20.02 (1.91) 22.80 (1.46) +1.70 (1.5) 21.08 (1.25)
Hormone therapy +0.78 (2.09) 20.13 (2.17) 20.15 (1.53) +1.15 (1.08) 21.93 (1.33) +0.06 (0.77)
Trastuzumab +0.72 (2.73) +1.99 (2.8) 25.19k (1.75) +0.71 (1.42) 20.03 (1.58) 20.10 (0.96)
Comorbidity
Obesity +5.38 (2.75) +3.34 (2.83) +3.43 (2.00) +2.71 (1.41) +1.26 (1.69) 20.20 (0.98)
Hypertension +3.82 (2.20) +0.79 (2.27) +2.25 (1.62) +2.08 (1.15) 20.13 (1.34) +0.77 (0.85)
Diabetes 24.73 (2.81) 21.30 (2.96) +1.42 (2.1) 21.30 (1.30) 21.69 (1.67) +0.17 (1.15)
Income, $ (ref. . $50,000)
, 15,000 +7.79 (4.54) +2.59 (4.40) +11.12¶ (3.22) +12.58¶ (2.46) 23.30 (2.06) +4.95 (2.80)
15,000-29,999 +13.92¶ (3.33) +8.73§ (3.4) +14.02¶ (2.65) +5.86¶ (1.53) +1.43 (2.06) +2.66§ (1.18)
30,000-49,999 +9.79¶ (2.86) +7.92k (2.95) +7.71¶ (2.12) +4.29¶ (1.44) +3.61 (1.96) +2.00§ (0.93)
Insurance (ref. private)
Medicare +8.01 (4.48) 26.20 (4.48) +9.15§(3.66) +5.94§ (2.38) 25.35k (1.89)
Medicaid +21.11¶ (3.75) +9.19k (3.72) +10.11¶ (2.61) +10.27¶ (1.93) +4.89§ (2.25)
Uninsured +28.45¶ (4.74) +20.42¶ (4.88) +26.93¶ (4.35) +7.18k (2.24) +8.74k(3.32)
Education (ref. college)
High school only +4.40 (3.87) +3.98 (3.94) +0.30 (2.41) 20.83 (1.45) 22.18 (2.69) 21.54 (2.75)
, High school 22.09 (4.24) 22.65 (4.31) 21.74 (2.76) 20.52 (1.85) 25.84k (2.84) 24.29 (2.75)
Marital status (ref. married)
Single 24.43 (3.27) 23.45 (3.33) 22.73 (2.07) 20.13 (1.49) +2.23 (1.92) +0.15 (1.06)
Widowed +0.59 (3.80) 20.85 (4.01) +1.19 (2.87) +0.35 (1.89) +2.40 (2.66) +1.14 (1.14)
Separated/divorced +6.35§ (2.67) +4.08 (2.73) +2.96 (1.93) +2.56 (1.39) +4.53k (1.67) +1.36 (1.04)
NOTE. Results are interpreted as average change in predicted risk of outcome relative to ref. category. Estimates are from logistic regressions that controlled for all other
characteristics listed. Bold indicates statistically significant (P , .05).
Abbreviation: ref., referent.
*Analysis excludes women who had never worked before diagnosis or declined to respond (n = 2,440).
†Analysis excludes women who had never worked before diagnosis (n = 2,480).




we eventually will examine the longer-term financial burden; cancer-
related outcomes such as endocrine therapy adherence, recurrence, 
and breast cancer–specific mortality; and emotional and physical 
sequelae associated with this financial burden.
An urgent need exists for research on the financial needs of 
diverse patients with breast cancer as well as for the development of 
interventions and support tools that identify and match patients to 
resources for financial assistance, can be delivered broadly across 
a variety practice settings, and are user friendly to facilitate dis-
cussions between patients and providers about addressing financial 
barriers to treatment. Policies and programs that help to limit and 
mitigate the effects of cancer-related financial strain are needed, 
including ensuring greater price transparency. Finally, providers 
should recognize and communicate with patients about the po-
tential for cancer-related financial strain and, where possible, of-
fer higher-value treatment alternatives, particularly for minority 
women who may be more financially vulnerable. In the absence of 
such interventions, black women will continue to shoulder a dis-
proportionate burden of cancer-related financial strain and 
downstream disparate cancer outcomes.
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Appendix
Table A1. Characteristics of Included Versus Excluded Study Participants
Characteristic Included, No. (%) Excluded, No. (%) P
No. of participants 2,494 422
Race
White 1,265 (51) 156 (37) < .001
Black 1,229 (49) 286 (63)
Mean age at diagnosis, years (SD) 52.4 (11.1) 48.6 (10.5) < .001
AJCC stage
1 1,088 (44) 101 (24) < .001
2 992 (40) 175 (42)
3 317 (13) 101 (24)
4 68 (3) 42 (10)
Treatment received
Mastectomy 1,242 (50) 234 (55) < .001
Chemotherapy 1,576 (63) 306 (72) < .001
Radiation 1,810 (73) 289 (68) .080
Endocrine therapy 1,740 (70) 223 (53) < .001
Trastuzumab 365 (15) 58 (14) .630
Comorbidity
Obesity 365 (15) 82 (19) .010
Hypertension 1,105 (44) 179 (42) .470
Diabetes 367 (15) 68 (16) .450
Annual household income, $
, 15,000 368 (16) 84 (21) .010
15,000-29,999 445 (19) 78 (20)
30,000-49,999 447 (19) 74 (19)
50,000 1,099 (46) 158 (40)
Insurance status
Private 1,853 (74) 260 (62) < .001
Medicare 145 (6) 21 (5)
Medicaid 361 (15) 104 (25)
Uninsured 134 (5) 35 (8)
Marital status
Single 228 (12) 73 (17) < .001
Married/living with partner 1,439 (58) 194 (46)
Widowed 204 (8) 31 (7)
Separated/divorced 562 (23) 123 (29)
Educational attainment
Did not complete high school 196 (8) 36 (9) .060
High school graduate 1,302 (52) 242 (58)
Some college/college graduate 996 (40) 143 (34)
NOTE. Analyses were t test (continuous) or x2 test (categorical) of included v excluded. Bold indicates statistically significant (P , .05).
Abbreviations: AJCC, American Joint Committee on Cancer; SD, standard deviation.
Table A2. Partially Adjusted Risk Differences: Adverse Financial Impact of Breast Cancer
Variable
Adjusted Risk Difference (SE)
Any Financial Impact Income* Loss Financial Barrier Transport Barrier Job† Loss Insurance‡ Loss
Black 14.09§ (2.11) 9.69§ (2.12) 10.12§ (1.59) 9.59§ (1.14) 6.41§ (1.27) 2.82§ (0.84)
Age 20.68§ (0.10) 20.50§ (0.10) 20.54§ (0.08) 20.16§ (0.06) 20.22k(0.06) 20.09¶ (0.04)
Stage (ref. stage 1)
2 3.80 (2.43) 3.86 (2.46) 20.78 (1.82) 2.40 (1.30) 1.19 (1.48) 0.38 (0.86)
3 9.70k (3.73) 5.76 (3.73) 1.95 (2.82) 4.40¶ (2.15) 1.25 (2.11) 0.53 (1.45)
4 18.52k (6.22) 17.37k (6.42) 6.02 (4.91) 7.29 (3.73) 11.66¶ (4.74) 20.74 (1.71)
Treatment received
Mastectomy 20.89 (2.47) 21.79 (2.48) 0.17 (1.83) 0.27 (1.35) 22.80¶ (1.43) 1.12 (1.00)
Chemotherapy 9.20§ (2.63) 9.73§ (2.65) 4.90¶ (1.90) 2.75 (1.41) 3.19¶ (1.54) 1.29 (0.86)
Radiation 21.56 (2.71) 0.23 (2.73) 21.14 (2.09) 23.93¶ (1.73) 1.54 (1.53) 21.40 (1.40)
Hormone therapy 0.09 (2.18) 20.33 (2.20) 20.19 (1.62) 1.25 (1.16) 21.70 (1.33) 20.06 (0.79)
Trastuzumab 0.43 (2.83) 1.84 (2.84) 25.06k (1.84) 0.54 (1.51) 20.10 (1.59) 20.15 (0.97)
Comorbidity
Obesity 6.39¶ (2.83) 3.67 (2.88) 3.95 (2.17) 3.43¶ (1.62) 1.44 (1.74) 20.26 (0.99)
Hypertension 6.65k (2.26) 2.46 (2.30) 4.51¶ (1.75) 3.43k (1.28) 0.49 (1.39) 0.99 (0.90)
Diabetes 22.93 (2.94) 20.66 (3.01) 2.78 (2.33) 20.12 (1.53) 21.45 (1.73) 0.41 (1.26)
NOTE. Results are interpreted as average change in predicted risk of outcome relative to ref. category. Estimates are from logistic regressions that controlled for all other
characteristics listed. Bold indicates statistically significant (P , .05).
Abbreviation: ref. referent.
*Analysis excludes women who had never worked before diagnosis or declined to respond (n = 2,440).
†Analysis excludes women who had never worked before diagnosis (n = 2,480).

















1. Unadjusted 1.48§ (0.06) 1.38§ (0.07) 2.21§ (0.21) 4.67§ (0.80) 2.21§ (0.29) 3.86§ (1.25)
2. Partially adjusted, including clinical factors only 1.34§ (0.06) 1.26§ (0.07) 1.85§ (0.19) 3.73§ (0.67) 1.96§ (0.27) 3.22§ (1.10)
3. Fully adjusted, including clinical factors and
socioeconomic status
1.13k (0.05) 1.13¶ (0.06) 1.17 (0.11) 1.59¶ (0.26) 1.52k (0.22) 1.75 (0.62)
NOTE. Results are interpreted as proportional change in predicted risk of outcome for black relative to white. Adjusted results are from logistic regressions that
controlled for additional characteristics. Model 2 adjusts for stage, receipt of mastectomy, chemotherapy, radiation therapy, hormone therapy, and trastuzumab,
and comorbidities. Model 3 adjusts for all clinical characteristics plus insurance, household income, education, and marital status. Bold indicates statistically significant
(P , .05).
*Analysis excludes women who had never worked prior to diagnosis or declined to respond (n = 2,440).
†Analysis excludes women who had never worked prior to diagnosis (n = 2,480).
‡Analysis is only for women privately insured at the time of the baseline survey (n = 1,852).
§P , .001.
kP , .01.
¶P , .05.
